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Introduction  
According to recent SEER Cancer Statistics, between 2005-2009 the overall cancer incidence 
and mortality rate was higher in men than in women [1]. This sex difference is also observed 
in non-melanoma skin cancer (NMSC), which includes both basal cell carcinoma (BCC) and 
squamous cell carcinoma (SCC).  Epidemiological studies demonstrate that men have twice 
the incidence of BCC and three times the incidence of SCC as women [2]. There are over 3.5 
million NMSC diagnoses in approximately 2 million patients each year [3] with treatment 
costs reaching over $1.4 billion [4], making it the fifth most costly cancer in the Medicare 
population [5]. While SCC only makes up 16% of all NMSC, it can metastasize more 
frequently, killing approximately 2500 people each year, of which men are the majority [6].  
A component of solar radiation, UVB is the major environmental carcinogen contributing to 
the development of both BCC and SCC [7-9]. Though the increased SCC incidence observed 
in men has been attributed to lifestyle differences with higher levels of sun exposure and less 
protection from the sun compared to women [10-12], we have previously shown using a 
murine model that when exposed to equivalent UVB doses, this sex bias still holds true [13]. 
With the increasing incidence of NMSC and the knowledge that men and women respond 
differently to UVB, it is imperative to examine the efficacy of potential treatments in both 
sexes. 
It is well documented that UVB exposure is associated with an inflammatory response [14-
16], which following both acute and chronic exposure, is known to play a role in the 
 formation of NMSC [17-19]. Chronic UVB exposure induces constitutive expression of 
cyclooxygenase 2 (COX-2), which is the primary source of elevated prostaglandin E2 (PGE2) 
in the skin [20,21]. This prostaglandin synthesis increase plays a key role in carcinogenesis 
by contributing to uncontrolled proliferation of damaged cells that ultimately form tumors 
[22-26]. The inflammatory response that coincides with elevated PGE2 levels is linked to 
increased DNA damage, which following exposure to stimuli such as UVB, induces the 
expression of wild type p53, a tumor suppressor gene [27]. The loss of function of p53 by 
mutation or allele loss is a common finding in many human malignancies, including 
cutaneous SCC [28,29].  
UVB exposure induces the production of reactive oxygen species such as hydrogen peroxide, 
which if not maintained at a homeostatic level by antioxidant networks, can cause oxidative 
stress and cellular damage. The main cutaneous antioxidant, catalase, has the role of 
detoxifying hydrogen peroxide. Skin antioxidant activity decreases with UVB exposure, and 
specifically, catalase activity level decreases have been associated with both skin 
carcinogenesis and progression [30-36]. Previously, we reported decreased antioxidant 
activity [13], and specifically, catalase activity [37], in the skin of male mice compared to 
female mice that may contribute to increased tumorigenesis in males. 
We previously demonstrated that treating female mice topically with the COX-2 inhibitor, 
celecoxib, decreased PGE2 levels as well as the percentage of p53-positive epidermal cells in 
the acute UVB-induced cutaneous response [38]. Chronic UVB exposure and subsequent 
topical celecoxib treatment decreased both tumor number and grade in female mice; however, 
its efficacy in males has not been described. Since male mice display lower levels of 
inflammation and antioxidant activity as compared to female mice after UVB exposure 
[13,37], we sought to investigate the extent to which a topical anti-inflammatory drug would 
 affect tumor burden as well as PGE2 or catalase levels in the skin of male versus female mice 
after chronic UVB exposure. 
Because celecoxib is not available to patients in a topical formulation, we conducted studies 
using topical diclofenac, an NSAID and COX-2 inhibitor, which is currently prescribed to 
patients with actinic keratotic lesions—precursors of SCC. Topical formulations are better 
tolerated and cause fewer adverse effects compared to oral COX inhibitors as the systemic 
levels are greatly decreased with topical treatments [39]. Open label studies have 
demonstrated that diclofenac is indeed well tolerated and effective short-term for treating 
actinic keratotic lesions [40,41]. However, its efficacy as a preventative agent in patients 
without evidence of precursor lesions but with significant UVB-induced cutaneous damage 
has not been examined. Additionally, potential differences between men and women in the 
efficacy of diclofenac treatment have not been reported. 
A recent case-control study suggested a dose-dependent, cumulative, protective effect for the 
reduction of skin cancer risk, specifically SCC, with the use of a number of NSAIDs [42]. In 
the current study, we have modeled both male and female compliant patients who eliminated 
sun exposure and began using topical diclofenac regularly to reverse existing damage 
resulting from chronic UVB exposure and prevent tumor development. Our results 
demonstrate that despite the observed sex differences in the inflammatory response, 
prolonged topical diclofenac treatment of chronically UVB-damaged skin effectively reduced 
tumor multiplicity in male and female Skh-1 hairless mice. Interestingly, with topical 
diclofenac treatment, tumor burden was significantly decreased and tumors were of lower 
histologic grade only in male mice. While PGE2 levels were decreased in both sexes, levels 
of the antioxidant, catalase, were increased with diclofenac treatment in male mice only.  
These data support inflammation as a key factor contributing to UVB-induced tumor 
development in both male and female mice. Taken together, our study emphasizes differences 
 in the response of male and female murine skin and demonstrates a potential new therapeutic 
use for this currently available topical treatment as a preventative intervention for patients 
predisposed to cutaneous SCC development.  
Materials and methods 
Mice 
Outbred, male and female Skh-1 mice (6-8 weeks old, Charles River Laboratories, 
Wilmington, MA) were housed in the vivarium at The Ohio State University according to the 
requirements established by the American Association for Accreditation of Laboratory 
Animal Care. All procedures were approved by the Institutional Animal Care and Use 
Committee before the initiation of any studies. Mice were dorsally exposed to 2240 J/m
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UVB, previously determined to be 1 MED, 3 weekly on non-consecutive days for 10 weeks. 
UVB dose was calculated using UVX radiometer and UVB sensor (UVP, Upland, CA) and 
emitted by Phillips FS40 UV bulbs (American Ultraviolet Company, Lebanon, IN). Mice 
were treated topically with vehicle (Surgilube; Savage Laboratories, Melville, NY) or 500 
g diclofenac (Solaraze, 3% diclofenac sodium; Doak Dermatologics, Fairfield, NJ) in 
vehicle for 15 weeks with no additional UVB exposure. This dose of diclofenac was chosen 
based on previous studies in our laboratory. Surgilube is an inert vehicle used clinically as a 
surgical lubricant. Tumors larger than 1 mm in diameter were measured weekly with calipers. 
After sacrifice, 0.5cm
2
 section of dorsal skin and all tumors were fixed as previously 
described [37] while remaining dorsal skin was snap frozen in liquid nitrogen.  
 Tumor Grading 
H&E stained tissue sections of tumors isolated from male and female mice were graded in a 
blinded manner by a board-certified veterinary pathologist (DFK) as previously described 
[13].  
Catalase Activity Assay 
Frozen dorsal skin was crushed and 15 mg was used for analysis of catalase activity using the 
Catalase Assay Kit (Cayman Chemical, Ann Arbor, MI) according to manufacturer’s 
instructions. 
Prostaglandin E2 EIA 
Frozen dorsal skin was crushed and 15 mg was used for analysis of PGE2 levels using the 
Prostaglandin E2 EIA Kit-Monoclonal (Cayman Chemical) according to manufacturer’s 
instructions. 
Immunohistochemistry 
p53: Paraformaldehyde-fixed/OCT-embedded dorsal skin sections were cut (10 µm) onto 
Superfrost Plus® microscope slides (Fisher Scientific) and stored at -80°C for future analysis. 
Slides were thawed overnight at room temperature, baked at 60°C for 30 min, and then 
rehydrated in Clear Rite 3 (Richard-Allen Scientific) and a graded series of ethanol. Sections 
were circled with Immedge pen (Vector Laboratories), and endogenous peroxidase activity 
was blocked with 3% H2O2 in water for 10 minutes at room temperature. Slides were 
incubated in Antigen Unmasking Solution (Vector Laboratories) for 25 min in a vegetable 
steamer reaching 95°C. Slides were cooled for 20 minutes at room temperature and blocked 
in 1 Casein (Vector Laboratories) for 10 minutes followed by incubation with primary p53 
antibody (clone CM5p, Novocastra (Leica Microsystems Inc.), Buffalo Grove, IL) at a 1:500 
 dilution in 1 Casein at room temperature for 1 hour. Slides were incubated in Rabbit Link 
and Label (Biogenex, Fremont, CA), each for 30 minutes at room temperature. Slides were 
washed in PBS containing 0.05% Tween (PBST) between the various incubation steps 
described above. Following a final PBST wash, slides were incubated in DAB solution 
(Vector Laboratories) for 10 minutes at room temperature. Slides were washed in deionized 
water, counterstained with Hematoxylin 2, and dehydrated in an increasing series of ethanol 
followed by Clear Rite 3, and then cover slipped with VectaMount mounting medium (Vector 
Laboratories). p53 foci were counted as 3 or more adjacent p53-positive cells and examined 
in 5 fields of view at 20 magnification.  
Ki67: Protocol is the same as above through incubation with 1 Casein. Slides were 
incubated with primary Ki67 antibody (Dako, Carpinteria, CA) at a 1:200 dilution in 1 
Casein overnight at 4°C in a humid chamber. Slides were incubated in biotinylated IgG 
(Vector Laboratories) at a 1:200 dilution in 1 Casein for 30 minutes at room temperature. 
Slides were incubated in ABC Elite (Vector Laboratories) for 30 minutes at room 
temperature. Slides were washed in PBST between the various incubation steps described 
above. Slides were incubated in DAB solution (Vector Laboratories) for 10 minutes at RT. 
Slides were washed in deionized water, counterstained, and dehydrated as above. Ki67-
positive cells were examined in 5 fields of view at 60 magnification. 
Statistical Analysis 
The results presented in this paper were part of a larger experiment involving four treatment 
groups (of which Diclofenac was one) and a single control group. Dunnett’s adjustment 
[43,44] for multiplicity was used for comparing the primary outcome of tumor burden at 24 
weeks between the treatment groups and control in order to restrict the probability of a type I 
error to 5%. The number of control mice was inflated compared to the treatment groups to 
 increase the power of the comparison [43]. Residual plots verified the model assumptions of 
normality and homoscedasticity and a logarithmic transformation was utilized if necessary. 
Continuous outcome data were analyzed using an ANOVA approach with linear contrasts for 
testing the comparisons of interest. A mixed-effects regression model with a random slope 
and intercept by subject was used to model tumor growth from the time of tumor origination. 
For count data, Poisson regression was used. All analyses were conducted in SAS version 9.2 
(SAS Institute, Cary, NC). p-values ≤0.05 were considered statistically significant.     
Results 
Diclofenac topical treatment decreased tumor number and burden  
To examine the effects of topical diclofenac treatment as a preventative agent against tumor 
development, we exposed male and female Skh-1 hairless mice to 2240 J/m
2
 UVB 
(previously determined to be 1 MED in our laboratory) for ten weeks to model chronic sun 
exposure. Mice were then topically treated with either surgilube (vehicle) or diclofenac for 15 
weeks without further UVB exposure to model a lifestyle change. Non-irradiated male and 
female mice treated with either vehicle or diclofenac did not develop tumors. Additionally, 
mice that received no vehicle treatment did not exhibit a significantly different tumor burden 
compared to mice treated with vehicle, indicating that the vehicle had no significant effect on 
tumorigenesis in this study (data not shown). 
Following 10 weeks of only UV exposure and 15 weeks of preventative topical treatment 
with diclofenac, male mice exhibited decreased tumor multiplicity with 57.8% fewer tumors 
compared to the mice treated with vehicle (p<0.0001, Figure 1A). At week 24, male mice 
treated topically with diclofenac exhibited significantly decreased tumor burden by 82.5% 
(p<0.0001) compared to the mice treated with vehicle (Figure 1B).  Female mice treated 
topically with diclofenac also demonstrated decreased tumor multiplicity with 63.1% times 
fewer tumors compared to mice treated with vehicle (p<0.0001, Figure 1A). Female mice 
 treated topically with diclofenac displayed a 51.7% decrease in average tumor burden that 
was not statistically different (p=0.1098) compared to mice treated with vehicle (Figure 1B). 
However, female mice treated with vehicle exhibited approximately half the tumor burden as 
vehicle-treated males, which was significantly different (p=0.0033). 
Examining the change in tumor burden over time, we found that male mice treated topically 
with diclofenac had a significantly decreased tumor growth rate of 6.9% while mice treated 
with vehicle exhibited a growth rate of 15.9% (p=0.0057, Figure 2A). Though female mice 
treated topically with diclofenac also exhibited a slight decrease in tumor growth rate 
compared to mice treated with vehicle, 8.6% versus 11.1%, respectively, this decrease was 





Figure 1 Diclofenac decreases tumor multiplicity and burden in male and 
female mice. Tumors with a diameter larger than 1 mm were measured weekly. (A) 
Male and female mice treated topically with diclofenac for 15 weeks after 10 weeks 
of UVB exposure exhibited decreased tumor multiplicity compared to the mice 
treated with vehicle (*p<0.0001). (B) At week 24, male mice treated topically with 
diclofenac exhibited significantly decreased tumor burden (*p<0.0001) compared to 





Figure 2 Diclofenac decreases tumor growth rate in male mice. Tumors with a 
diameter larger than 1 mm were measured weekly. (A) Male mice treated topically 
with diclofenac had a decreased tumor growth rate (*p=0.0057) compared to mice 
treated with vehicle. (B) Female mice treated topically with diclofenac exhibited a 
slight decrease in tumor growth rate compared to mice treated with vehicle that was 




 Diclofenac topical treatment decreased the severity of tumors in male mice 
Tumors were isolated from mice after 10 weeks of UVB exposure followed by 15 weeks of 
topical treatment and scored by a board-certified veterinary pathologist (DFK). Tumors 
classified as papilloma were considered benign and those classified as microinvasive or fully 
invasive SCC were considered malignant. Male mice treated with vehicle developed tumors 
of each grade while male mice preventatively treated with diclofenac developed tumors 
graded as papilloma (grades 1-3) or microinvasive SCC (grade 1 only). As seen in Table 1, 
male mice treated with vehicle, 19.3% of graded tumors were malignant while male mice 
treated topically with diclofenac developed malignant tumors consisting of only 5.9% of 
graded tumors. There was a trend towards a lower malignancy rate, but it was not statistically 
significant (p=0.2413). Importantly, male mice treated with diclofenac developed no fully 
invasive SCC lesions while mice treated with vehicle developed 5.3% of graded tumors that 
were fully invasive SCC lesions.  
 
 % Premalignant Tumors % Malignant Tumors 
Male Vehicle 80.7 19.3 (5.3% SCC) 
Male Diclofenac 94.1 5.9 (No SCC) 
Table 1. Distribution of tumor grades in male mice. 
 
Female mice treated with vehicle developed all grades of papilloma, microinvasive SCC 
grade 1 and fully invasive SCC. Mice preventatively treated with diclofenac developed all 
grades of papilloma, microinvasive SCC grades 1 and 2, and fully invasive SCC. 
 Interestingly, while female mice treated topically with diclofenac exhibited decreased tumor 
burden compared to vehicle-treated mice, the estimated per tumor malignancy rate was 0.25 
compared to 0.11 for mice treated with vehicle, which trended towards an increased 
malignancy rate but was not statistically significant (p=0.2574). 
 
 % Premalignant Tumors % Malignant Tumors 
Female Vehicle 89.7 10.3 
Female Diclofenac 75.0 25.0 
Table 2. Distribution of tumor grades in female mice. 
 
Diclofenac topical treatment increased catalase activity levels in male mice 
Protein was extracted from tumor-free, dorsal skin in order to examine catalase activity 
levels. Even after 15 weeks without UVB exposure, catalase activity levels were significantly 
decreased in the vehicle-treated male skin as compared to the non-irradiated controls 
(p=0.0004, Figure 3A), but not in female skin (p=0.2121, Figure 3B). Topical diclofenac 
treatment applied to male skin significantly increased catalase activity from levels observed 
in the vehicle-treated skin (p=0.0035, Figure 3A), and in fact, catalase activity is almost 
restored to levels observed in non-irradiated skin. In contrast, catalase activity levels in 
female skin treated topically with diclofenac were not significantly altered compared to those 
observed in vehicle-treated skin (p=0.1590, Figure 3B).  
 Diclofenac topical treatment decreased cutaneous Prostaglandin E2 (PGE2) levels  
To confirm that topical diclofenac treatment preventatively applied effectively inhibited 
COX-2-mediated PGE2 production, cutaneous PGE2 levels were determined by enzyme 
immunoassay. In chronically irradiated male (Figure 4A) and female (Figure 4B) vehicle-
treated skin, even after 15 weeks without UVB exposure, PGE2 levels were significantly 
increased from levels observed in non-irradiated skin (p<0.0001). Skin of male (Figure 4A) 
and female (Figure 4B) mice exposed to UVB for 10 weeks and treated topically with 
diclofenac for 15 weeks exhibited significantly decreased PGE2 levels as compared with 









Figure 3 Diclofenac increases catalase activity in male skin. Even after 15 
weeks without UVB exposure, catalase activity levels were significantly decreased 
in the vehicle-treated male skin (A) as compared to the non-irradiated controls 
(*p=0.0004). With topical diclofenac treatment in male skin, catalase activity levels 
were significantly increased from levels observed in the vehicle-treated skin 
(*p=0.0035). (B) Catalase activity levels were not significantly altered in female 

























Figure 3.5 Diclofenac topical treatment decreases cutaneous PGE2 levels in 
male and female mice. Cutaneous PGE2 levels were determined by enzyme 
immunoassay after 10 weeks of UVB exposure and 15 weeks subsequent topical 
treatment. In both male (A) and female (B) mice, PGE2 levels were significantly 
increased with UVB exposure compared to levels observed in unirradiated mice 
(*p<0.0001). Skin of male (A) and female (B) mice exposed to UVB for 10 weeks 
and treated topically with diclofenac for 15 weeks exhibited significantly decreased 
PGE2 levels as compared with chronically irradiated vehicle-treated skin 
(*p=0.0001). 

















 Male mice have increased numbers of p53-positive foci compared to female mice 
Tumor-free, dorsal skin sections were examined for p53-positive foci via 
immunohistochemistry with an antibody detecting both wild type and mutant p53 (Figure 5A 
and B). The number of p53-positive foci measured over five fields was not significantly 
altered with preventative topical diclofenac treatment in male skin (2.5 for vehicle-treated vs 
1.8 for diclofenac-treated, p=0.2323) or female skin (0.89 for vehicle-treated vs 0.63 for 
diclofenac-treated, p=0.4918). Corresponding with the increased tumor burden, the mean 
number of foci was significantly higher in vehicle-treated male skin compared to vehicle-
treated female skin (2.5 vs 0.89, p=0.0004, Figure 5C). 
Diclofenac does not affect proliferation 15 weeks after cessation of UVB exposure 
Tumor-free, dorsal skin sections were stained for Ki67. The percentage of Ki67-positive cells 
was not different (p=0.4708) between the vehicle-treated and diclofenac-treated male skin 
after 10 weeks of UVB exposure followed by 15 weeks of topical treatment with no 
additional UVB exposure. In female skin, the percentage of Ki67-positive cells exhibited a 
decreasing trend from 13.4% to 9.4% with preventative topical diclofenac treatment 
compared to vehicle-treated mice (p=0.0596). Interestingly, the percentage of Ki67-positive 
cells was significantly higher in male skin compared to female skin with both vehicle and 




















Figure 3.6 Male mice have increased numbers of p53-positive foci compared 
to female mice. Dorsal, tumor-free, skin sections were examined for p53-positive 
foci via immunohistochemistry with an antibody detecting both wild type and mutant 
p53. Representative (A) male and (B) female vehicle-treated skin after 10 weeks of 
UVB and 15 weeks of treatment. Scale bar = 10 m. The mean number of foci per 
field of view was significantly higher (C) in vehicle-treated male skin compared to 









Our previous studies have demonstrated that when exposed to equivalent, chronic UVB light, 
male mice exhibit a higher tumor burden compared to female mice [13], which we confirmed 
in the current study. We also have previously shown that female mice preventatively treated 
topically with the anti-inflammatory drug, celecoxib exhibited decreased tumor number, 
grade, PGE2 levels, and the number of p53-positive cells [20,38]. In the current study, we 
show that the readily available and currently used NSAID, diclofenac, elicits similar results 
in male mice treated topically with diclofenac after sustaining significant UVB damage. We 
demonstrate that prolonged, topical diclofenac treatment of chronically UVB-damaged skin 
Figure 3.7 Male skin displays higher levels of proliferation regardless of 
treatment. Dorsal, tumor-free, skin sections were stained for Ki67. Male skin 
exhibited higher percentages of Ki67-positive cells compared to female skin with 
both vehicle (*p<0.006) and diclofenac topical treatment (**p=0.0004). 
 effectively reduced tumor multiplicity in both sexes. Unexpectedly, tumor burden was only 
significantly decreased in male mice, where we also observed a slower rate of growth and a 
trend toward a lower malignancy rate, with no fully invasive squamous cell carcinomas 
developing in diclofenac-treated male mice. We also observed a sex difference in catalase 
activity in that male mice treated with diclofenac exhibited increased catalase activity levels 
compared to vehicle-treated male mice while catalase activity levels in female mice remained 
unchanged. 
The observed increase in catalase activity levels in male skin may be an important factor 
because we have observed endogenously lower antioxidant activity levels [13] and 
specifically, lower catalase activity levels in male skin [37]. Additionally, both decreased 
antioxidant enzyme levels and the resulting oxidative protein damage in chronically UV-
exposed skin have been demonstrated [33]. Recently we reported a link between decreased 




 myeloid cell infiltration, and increased 
tumorigenesis in male mice but not in female mice [37]. Elevated levels of PGE2 have been 




 myeloid cells that produce 
high levels of reactive oxygen species (ROS) [45,46]. By decreasing PGE2 levels in male 




 myeloid cell infiltration is decreased 
(unpublished data), therefore decreasing myeloid-associated ROS levels. As a result, catalase 
activity levels may be increased or maintained due to the overall lower levels of cutaneous 
ROS production. The increased skin catalase activity in male mice treated with diclofenac 
compared to male mice treated with vehicle may indicate that restoration of this antioxidant is 
important for decreasing tumorigenesis in male but not in female mice.  
In addition to increasing catalase activity, diclofenac topical treatment also reduced the 
number of p53-positive foci observed in male mice. Though not statistically significant, there 
is a clear trend towards fewer foci observed. As p53 is indicative of overall DNA damage, a 
 decrease in the number of p53-positive cells observed demonstrates that diclofenac treatment 
may be promoting repair or preventing damage altogether. Previous studies demonstrate that 
ingenol mebutate, a well-tolerated topical antineoplastic drug used for treatment of both 
NMSC and actinic keratotic lesions [47-49], effectively reduced UVB-induced lesions and 
p53 patches in Skh-1 mice [50]. However, the side effects of this treatment included scar 
formation and skin tightening, which were not observed in the current study. Because the 
mice in the current study were exposed to UVB for 10 weeks and then treated for 15 weeks 
without further UVB exposures prior to examining tissue, further studies examining various 
time points in addition to examining levels of mutated p53 would be necessary to determine 
the role diclofenac is playing in the formation of p53 foci. 
Importantly, preventative diclofenac treatment led to decreased tumor burden in male mice 
and significantly lower PGE2 levels in both sexes compared to vehicle-treated mice, 
underscoring the importance of COX-2-mediated inflammation in the UVB-induced 
carcinogenesis process. PGE2 also contributes to angiogenesis [51] and invasion [52-55], in 
addition to inflammation. Notably, angiogenesis has been reportedly increased in actinic 
keratoses compared to adjacent skin [56]. Further, studies have indicated that an “angiogenic 
switch” is turned on during this stage, which contributes to the invasive nature and 
progression of these lesions toward becoming SCCs [57,58]. While not examined in the 
current study, blocking PGE2 production with diclofenac treatment may be decreasing 
angiogenesis and invasive properties that contribute to the lack of development of fully 
invasive SCC lesions in male mice that are present in the vehicle-treated mice. 
We have previously shown that males have lower levels of acute UVB-induced inflammation 
compared to female mice and suggested that the inflammatory response was not as important 
to tumorigenesis in male mice [13]. This study offers support to the fact that the 
inflammatory response in male mice, regardless of magnitude, is indeed important for 
 tumorigenesis, since decreasing levels of inflammatory mediators and increasing the 
antioxidant capacity within male skin correlated with decreased tumor number and burden in 
male mice topically treated with diclofenac.  
Recent studies have refocused on the preventative effects of NSAIDs against skin cancer 
[42,59], highlighting the relevance of our study. While many studies focus on oral NSAIDs 
that may result in harmful side effects over time, the use of topical NSAIDs results in lower 
systemic levels and therefore, a lower risk of these side effects including gastrointestinal 
hemorrhage and peptic ulcer disease [39,60]. Our data demonstrates a potential NSAID 
alternative for patients with cardiac or other health issues that may be heightened with oral 
NSAID use. 
In summary, we have shown in a model of UVB-induced SCC that topically treating male 
and female Skh-1 hairless mice prophylactically with the NSAID and COX-2 inhibitor, 
diclofenac, decreased tumor multiplicity and PGE2 production in both sexes. In addition, 
topically applied diclofenac also interestingly increased skin catalase levels and decreased 
tumor burden as well as the percentage of malignant tumors in male mice. These findings are 
especially relevant because in humans, men have a greater risk and incidence of cancer 
overall [1], with a three fold greater incidence of SCC [2]. To the best of our knowledge, this 
is the first report of a sex-associated difference in the efficacy of topical diclofenac treatment, 
implying that it may be beneficial to retrospectively dissect out potential sex-based 
differences in previously reported clinical outcomes in order to more effectively treat each 
sex. As we previously observed that male mice have lower antioxidant activity as compared 
with female mice, further studies are needed to determine if the increased catalase levels are 
contributing to the therapeutic effects of the diclofenac treatment, or if inhibiting 
inflammation is indeed the primary factor in both sexes. Overall, our data suggest that 
sustained diclofenac treatment applied topically to chronically UVB-damaged skin before the 
 appearance of precursor lesions, in combination with the elimination of UVB exposure, may 
be beneficial to patients who are predisposed to developing SCC. 
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